• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶解状态与标准剂量和低剂量冠状动脉内链激酶成功再灌注的关系。

Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase.

作者信息

Rothbard R L, Fitzpatrick P G, Francis C W, Caton D M, Hood W B, Marder V J

出版信息

Circulation. 1985 Mar;71(3):562-70. doi: 10.1161/01.cir.71.3.562.

DOI:10.1161/01.cir.71.3.562
PMID:3971527
Abstract

The influence of a systemic lytic state on reperfusion obtained after intracoronary streptokinase (SK) therapy has been evaluated in 15 patients with acute myocardial infarction and complete coronary occlusion. Coronary angiographic studies and measurements of blood fibrinolytic parameters were repeated at 15 min intervals during the infusion of a standard dose of SK and were compared with the results with approximately one-tenth the standard dose. Successful reperfusion was obtained in only 20% (2/10) of patients receiving the low dose, compared with a 75% to 80% success rate in patients receiving the standard dose as initial treatment (4/5) or as follow-up treatment of patients in whom low-dose therapy failed (6/8). There was a striking association between reperfusion and development of the lytic state in that all 12 treatments resulting in reperfusion also caused a lytic state and all seven treatments that failed to produce a lytic state also failed to induce reperfusion (p less than .001). Among the successfully treated patients, the dose of SK that induced a lytic state was relatively constant. However, coronary arterial thrombi differed in susceptibility to treatment. Sensitive thrombi (5/12) dissolved before the lytic state occurred and at a lower SK dose than that needed to cause a lytic state; more resistant thrombi (7/12) required a longer time and a significantly larger SK dose to dissolve. These results indicate that intrinsic properties of the thrombus influence the rate and outcome of treatment and that a minimal dose of SK (about 200,000 U) is required to ensure lasting reperfusion in susceptible patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在15例急性心肌梗死且冠状动脉完全闭塞的患者中,评估了全身纤溶状态对冠状动脉内注射链激酶(SK)治疗后再灌注的影响。在输注标准剂量SK期间,每隔15分钟重复进行冠状动脉造影研究和血液纤溶参数测量,并与约十分之一标准剂量的结果进行比较。接受低剂量治疗的患者中只有20%(2/10)成功实现再灌注,而接受标准剂量作为初始治疗的患者(4/5)或作为低剂量治疗失败患者的后续治疗的患者(6/8)的成功率为75%至80%。再灌注与纤溶状态的发展之间存在显著关联,即所有导致再灌注的12次治疗均引起了纤溶状态,而所有7次未能产生纤溶状态的治疗也未能诱导再灌注(p<0.001)。在成功治疗的患者中,诱导纤溶状态的SK剂量相对恒定。然而,冠状动脉血栓对治疗的敏感性不同。敏感血栓(5/12)在纤溶状态出现之前溶解,且所需的SK剂量低于引起纤溶状态所需的剂量;更具抗性的血栓(7/12)需要更长时间和显著更大剂量的SK才能溶解。这些结果表明,血栓的内在特性影响治疗的速度和结果,并且需要最小剂量的SK(约200,000 U)以确保易感患者实现持久再灌注。(摘要截短至250字)

相似文献

1
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase.溶解状态与标准剂量和低剂量冠状动脉内链激酶成功再灌注的关系。
Circulation. 1985 Mar;71(3):562-70. doi: 10.1161/01.cir.71.3.562.
2
Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.急性心肌梗死中静脉注射茴香酰化纤溶酶原链激酶激活剂复合物与冠状动脉内注射链激酶的比较。
Am J Cardiol. 1988 Jul 1;62(1):25-30. doi: 10.1016/0002-9149(88)91359-8.
3
Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction.临床进展性心肌梗死患者冠状动脉内输注链激酶后左心室功能的变化
Am Heart J. 1981 Dec;102(6 Pt 2):1188-93. doi: 10.1016/0002-8703(81)90651-7.
4
Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial.
Circulation. 1989 Nov;80(5):1166-75. doi: 10.1161/01.cir.80.5.1166.
5
Coronary artery reperfusion in acute myocardial infarction: beneficial effects of intracoronary streptokinase on left ventricular salvage and performance.
Am Heart J. 1981 Dec;102(6 Pt 2):1168-77. doi: 10.1016/0002-8703(81)90648-7.
6
Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.静脉注射茴香酰化纤溶酶原链激酶激活剂复合物或冠状动脉内注射链激酶治疗后的纤维蛋白原浓度与冠状动脉再灌注
Drugs. 1987;33 Suppl 3:237-41. doi: 10.2165/00003495-198700333-00044.
7
Systemic markers of fibrinolysis after unsuccessful intracoronary streptokinase thrombolysis for acute myocardial infarction. Does nonreperfusion indicate failure to achieve a systemic lytic state?急性心肌梗死冠状动脉内链激酶溶栓失败后的纤溶系统标志物。再灌注未成功是否表明未能达到全身纤溶状态?
Am J Cardiol. 1984 Oct 1;54(7):712-7. doi: 10.1016/s0002-9149(84)80195-2.
8
Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction.急性心肌梗死中静脉及冠状动脉内注射链激酶的前瞻性随机试验。
Circulation. 1983 Nov;68(5):1051-61. doi: 10.1161/01.cir.68.5.1051.
9
Quantitative coronary angiography during intracoronary streptokinase in acute myocardial infarction: how long to continue thrombolytic therapy?
Cathet Cardiovasc Diagn. 1983;9(1):9-18. doi: 10.1002/ccd.1810090103.
10
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.
Ann Intern Med. 1986 Mar;104(3):304-10. doi: 10.7326/0003-4819-104-3-304.

引用本文的文献

1
Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.链激酶。老年患者急性心肌梗死中其药理学及治疗效果的综述
Drugs Aging. 1994 Jan;4(1):63-86. doi: 10.2165/00002512-199404010-00007.
2
Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.含链激酶溶栓药物的给药前抗体水平及疗效
Br Heart J. 1994 Sep;72(3):222-5. doi: 10.1136/hrt.72.3.222.
3
Bleeding complications of intracoronary fibrinolytic therapy in acute myocardial infarction. Assessment of risk in a randomised trial.
急性心肌梗死冠状动脉内溶栓治疗的出血并发症。一项随机试验中的风险评估。
Br Heart J. 1985 Nov;54(5):455-9. doi: 10.1136/hrt.54.5.455.
4
Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.茴香酰化纤溶酶原链激酶激活剂复合物和链激酶治疗急性心肌梗死的全身效应。荷兰侵入性再灌注研究的凝血方面。
Drugs. 1987;33 Suppl 3:242-6. doi: 10.2165/00003495-198700333-00045.
5
Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.静脉注射茴香酰化纤溶酶原链激酶激活剂复合物或冠状动脉内注射链激酶治疗后的纤维蛋白原浓度与冠状动脉再灌注
Drugs. 1987;33 Suppl 3:237-41. doi: 10.2165/00003495-198700333-00044.
6
Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.对茴香酰化纤溶酶原链激酶激活剂复合物静脉治疗急性心肌梗死的早期临床评估。
Drugs. 1987;33 Suppl 3:112-6. doi: 10.2165/00003495-198700333-00018.
7
Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?
Klin Wochenschr. 1986 Apr 1;64(7):301-6. doi: 10.1007/BF01711946.
8
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.溶栓疗法在急性心肌梗死和不稳定型心绞痛治疗中的应用
Drugs. 1989 Feb;37(2):191-204. doi: 10.2165/00003495-198937020-00006.
9
Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.对急性心肌梗死患者使用茴香酰化纤溶酶原链激酶激活剂复合物和链激酶的血液学影响。IRS II研究中期报告。
Drugs. 1987;33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.
10
A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.急性心肌梗死中阿尼普酶(茴香酰化纤溶酶原链激酶激活剂复合物,APSAC)的全身非溶解状态及局部溶栓失败
Br Heart J. 1990 Dec;64(6):355-8. doi: 10.1136/hrt.64.6.355.